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ABSTRACT  
A new α,α-disubstituted constrained glutamine analogue was designed to decorate gold-
nanoparticles and to induce 310-helix when inserted in peptides. Using an efficient “one-pot” 
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asymmetric Schmidt reaction, between 4-disubstituted-cyclohexanone and hydroxyalkylazides, 1H-
azepine-2-oxo-5-amino-5-carboxylic acid, (oxo-Azn) was prepared. The main (R) isomer was 
inserted at the N-terminus in a very short peptide sequence, i.e. PhCO-(R)-Oxo-Azn-L-Ala-Aib-L-
AlaNHMe and a stable 310-helix conformation was obtained, as verified by both NMR experiments 
and molecular dynamics (MD) simulations. Finally, the presence of the hydroxyl chain at nitrogen 
atom of the ring allowed the preparation of covered chiral gold nanoparticles.  
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Introduction 
Small molecules functionalized gold nanoparticles (GNPs) are at the forefront of the research in 
nano chemistry.1 The three dimensional self-assembled monolayers constructed by the introduction 
of organic compounds on GNPs have emerged as versatile tools of surface modification. 
Furthermore, the organic monolayer reduces the surface energy of GNPs and thus provides 
increased solubility and colloidal stability.2  
Amino acids and peptides are effective building blocks to create hierarchical nanomaterials 3 and 
functionalized GNPs. 4 They feature a multitude of functionalities and unique secondary structures 
based on controllable primary sequences and environmental conditions.5 By using amino acids and 
peptides, it is thus possible to tailor new hybrid materials for a broad range of applications in 
different areas, such as medicine, bionanotechnology, and electrochemistry.6 On the other hand, 
focusing on biomedical applications, the peptide instability toward proteases might be a concern. 
Synthetic analogs of natural amino acids represent valuable tools to overcome this problem.3b,7 In 
particular, the use of -disubstituted derivatives gives the double advantage of reducing the 
metabolic degradation, and of stabilizing the helical conformation, by reducing the available 
conformational space of the peptide backbone.8 
Continuing our researches on unnatural constrained amino acids, 9 we, recently, prepared a α,α-
disubstituted ornithine analogue, i.e. 1H-azepine-4-amino-4-carboxylic acid (Azn), as an effective 
310-helix inducer.
9c Reasoning on the possibility to use this scaffold as the key material to decorate 
gold nanoparticles, we designed, a -disubstituted cyclic glutamine analogue, i.e. 1H-azepine-2-
oxo-5-amino-5-carboxylic acid, named Oxo-Azn, containing on the nitrogen side chain a hydroxy 
tethering group (Figure 1).  
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Figure 1. Chemical structures of Azn and Oxo-Azn 
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Oxo-Azn was prepared using a very efficient one-step asymmetric Schmidt reaction that gives a 
mixture of “quasi enantiomers”, easily separated by chromatography (Scheme 1). The main (R) 
isomer was thus inserted at the N-terminus in a very short peptide sequence, i.e. PhCO-(R)-Oxo-
Azn-L-Ala-Aib-L-AlaNHMe. A stable 310-helix conformation was obtained, as verified by both 
NMR experiments and molecular dynamics (MD) simulations. Finally, taking advantage of the 
tethering group, covered chiral gold nanoparticles have been prepared and fully characterized.  
RESULTS AND DISCUSSION 
Synthesis of Oxo-Azn scaffold. 1H-azepine-2-oxo-5-amino-5-carboxylic derivatives 5/6 were 
synthesized through an asymmetric Schmidt reaction10 on cyclohexanone 19c and benzyl or phenyl 
substituted hydroxyalkylazides (2a,b) (Scheme 1) The reaction was performed in CH2Cl2 and in the 
presence of an excess of BF3∙OEt2 (from -80 to 25 °C). After 48 h, the reaction was quenched with 
2N NaOH affording a mixture of “quasi enantiomers” 5 and 6 (5a/6a: 67:33, 80%; 5b/6b: 50:50, 
75%; 1H NMR and HPLC analyses). A similar diastereoselection and yield were obtained by 
changing the temperature (from -10 to 25 °C) and the reaction time (18 h). 
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Scheme 1. Asymmetric Schmidt reaction on ketone 1. 
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To gain insight on the mechanism and diastereoselection, the reaction between 1 and 2a was 
monitored by 1H NMR. After 18 h, 1 H NMR analysis of the crude, before NaOH quenching, showed 
the formation of intermediates 3a/4a in 67:33 ratio. This mixture was crystallized from Et2O 
affording the pure bicyclic intermediate 4a (13%). Pure azepinone derivatives 5a (45%) and 6a 
(10%) were isolated after column chromatography of the mother liquors. (Scheme 2).  
Finally, the treatment of 4a with NaOH (2N, 24 °C, 30 min.) gave the minor stereoisomer 6a in 
quantitative yield (Scheme 1). X-Ray of the single crystal of 4a (Figure 2) allowed to assign 
unequivocally the stereochemistry of each adduct (for NMR discussion see Supporting 
Information). 
 
Figure 2. ORTEP plot of 4a at 293 K with atom numbering scheme; ellipsoids of non-H atoms at 
30% probability level. 
The isolation of the rigid bicyclic intermediate 4a allowed to confirm that the mechanism of 
formation of “quasi enantiomers” 5/6 is the one proposed by Aubè et al. 10 Accordingly, the 
azidoaddition occurs on ketone 1 possessing the chair conformation bearing the amido group in the 
equatorial position (confirmed as the most stable by theoretical calculations). In this way a couple 
of diastereoisomeric spiro intermediates A and A' that differ for the stereochemistry of nitrogen 
leaving group, is formed. Consequently to the departing of N2, the antiperiplanar migration of the 
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methylene group of cyclohexyl ring occurs affording, from A, bicyclic salt 3, and from A', salt 4 
(Scheme 1). 
Although the reaction occurred via the same mechanism, we found a different distribution of the 
diastereomers, with respect to literature data on 4-mono-substituted cyclohexanones. As an 
example-10a the Schmidt reaction between 4-tert-butylcyclohexanone and azide 2b leads to the S 
diastereoselection through the stabilization of intermediate A’ by cation- interaction. In our case, 
using the same azide, no diastereoselection was observed, suggesting that steric factors drive the 
diastereoselction outcome. This hypothesis is confirmed by the partial diastereoselection found in 
the case of azide 2a, containing the more flexible benzyl substituent. In this case, the minimization 
of steric interactions between the nitrogen leaving group and the benzyl substituent favours the 
formation of intermediate 3a with respect to 4a. 
Synthesis of tetrapeptide PhCO-(R)-Oxo-Azn-L-Ala-Aib-L-AlaNHMe. The model peptide PhCO-
(R)-Oxo-Azn-L-Ala-Aib-L-AlaNHMe was then prepared starting from -amino acid 5a (Scheme 
2). The sequence Ala-Aib-Ala has been deeply investigated in the literature, using both experimental 
techniques (NMR, CD, X-ray) and MD.11 In all studies, it has been emerged that multiple 
conformations are present, and that it is necessary to increase the length of the peptide chain to 
obtain stable helical conformations. Regarding Oxo-Azn, R-isomer was selected since it is known 
that only the R-Azn isomer, (see Figure 1), is able to induce a 310-helix when inserted in a short 
pentapeptide containing L-amino acids.9c  
In order to have in hand the necessary quantity of scaffold 5a for the peptide synthesis’ optimization, 
the reaction between ketone 1 and azide 2a was scaled up to 11g of 1, yielding 5a in 47% yield after 
column chromatography purification. The ester function on scaffold 5a was hydrolyzed using a 
methanolic solution of NaOH (2N) in CH2Cl2/MeOH (9:1, 25 °C, 15h). Acid 7 was isolated in 95% 
yield. Compound 7 was made to react with alanine benzyl ester p-toluenesulfonate [HOAt (1 
equiv.)/EDC (1 equiv.)/DIPEA (2 equiv.), CH2Cl2 25 °C, 2 h] affording dipeptide 8 (58% yield). 
The yield of 8 were increased (80%) using the free amine derivative of alanine operating with the 
same condensative conditions (15h). The benzyl group of the ester function was removed by 
hydrogenolysis (Pd/C, MeOH, 25 °C, 24h) giving acid 9 (90%, Scheme 3). The final tetrapeptide 
10 (50%) was obtained by reaction of 9 with dipeptide H2N-Aib-L-Ala-CONHMe
 [HOAt 
(1equiv.)/EDC (1equiv.)/DIPEA(2 equiv.), CH2Cl2 25 °C, 15 h]. It has to be underlined that in these 
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reaction conditions the epimerization of the alanine stereocenter was not observed (HPLC analysis, 
Figure S4 in the Supporting Information). Any attempt to synthesized directly compound 10 from 
5a and H2N-L-Ala-Aib-L-Ala-CONHMe tripeptide failed, probably for the steric hindrance on the 
carboxylic function of 7. 
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Scheme 2. Synthesis of tetrapeptide PhCO-(R)-Oxo-Azn-L-Ala-Aib-L-AlaNHMe 
Tetrapeptide 10 was first purified by preparative RP-HPLC. During the purification we observed 
the formation of a by-product, corresponding to the bicyclic derivative 11 (Figure 3; see supporting 
information for NMR discussion). Its formation must be ascribed to the TFA present in the RP-
HPLC eluent phases that catalysed the oxazoline ring formation. To overcome this issue, compound 
10 was directly purified by crystallization (CH2Cl2/Et2O) of the crude reaction mixture.  
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Figure 3. Chemical structure of 11, the product of transformation of 10 in acidic conditions 
NMR conformational studies on model peptide 10. A full assignment of the protons of peptide 10 
was accomplished by 500 MHz NMR analysis (1H, 13C, COSY, TOXY and HSQC NMR 
experiments, see Supporting Information). 2D-NOESY at different mixing times and temperature-
dependent chemical shift variation experiments (from 273 to 333 K) were performed in CD3CN 
solution, to obtain detailed information on the conformational behavior of 10. 
A complete set of  N,N (i,i + 1) NOE cross-peaks [PhCONH/Ala-2 (w); Ala-2/Aib (m); Aib/Ala-
4(vs)] were detected excepting for Ala-4/MeNH that are overlapped (Figure 4A). 
A)       B) 
 
 
 
 
 
 
 
 
 
Figure 4. Sections of the NOESYspectrum of 10 (10.2 mM CD3CN solution, 500 MHz, 25 °C, 500 
ms mixing time): A) NH/NH and B) -H/NH N.o.e. regions. 
Various NOEs are operative in the peptide chain, i. e. ,N (i,i+1) between Ala-2/Aib (m), and Ala-
4/NHMe (w). (Figure 4B) Longer range ,N (i,i+2)  and α,N (i,i+4)NOEs allow to define the helix 
types: the former is typical of a 310-helix, while the latter is typical of an α-helix.9c In our case, of 
relevance, are the long range N.o.e of Ala-2/Ala-4 [,N(i,i+2; w), (Figure 4B) and of the phenyl 
ring of benzyl moiety (δ 7.94) and the methyl of Aib (δ 1.54, m) (Figure 5). A further long range 
Noesy was detected between Ala-2 and NHMe [,N(i,i+3; m)]. All these data are in agreement with 
a 310-helix conformation. 
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Figure 5. Section of the NOESYspectrum of 10 (10.2 mM CD3CN solution, 500 MHz, 25 °C, 300 
ms mixing time): NH/-H N.o.e. region. 
13C values of the anysotropic Me of Aib that are in a magnetically inequivalent environment  such 
as in a helix structure, differ of more than  2 ppm.11a In our case δ 13C values of 23.0 and 26.4 were 
found for Aib-Me groups. NH chemical shifts temperature dependences, providing information on 
inaccessible or intramolecular H-bonds9c confirmed the helix structure, too. Values of -3.98 ppb K-
1 for Oxo-Azn, -3.99 ppb K-1  for Ala-2, -2.57 ppb K-1 for Aib, -1.55 ppb K-1 for Ala-4 and -2.64 
ppb K-1 for NHMe were detected (Figure 6). 
 
Figure 6. Temperature dependence of the NH proton chemical shifts of compound 10. 
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These data suggest that NH of Aib, Ala-4, and NHMe fall within the typical ranges for 
intramolecularly H- bonded protons. Conversely, an equilibrium between an intramolecularly H-
bonded and a non-H-bonded state is suggested for the NH of PhCONH and Ala-2 on the basis of 
temperature dependences (about 4 ppb K-1, Figure 6). 
From these findings we can postulate that a regular 310-helix construct, stabilized by three 
consecutive, i + 3 → i N-H…O=C intramolecular H-bonds (NH-3/PhCO, NH-4/ OxoAznCO, and 
NHMe/ Ala2CO) was formed. On the other hand, differently to similar compounds reported in the 
literature12, we did not detect any intramolecular H-bond between the CO group of the lactame 
function and the NH of peptide chain that could compete in the helix formation. Therefore, it has to 
be stressed the ability of Oxo-Azn to strongly stabilize 310-helix even if in very short peptides. 
Molecular Dynamics (MD) studies on model peptide 10. To evaluate the folding behavior of (R)-
Oxo-Azn, we also performed Replica Exchange Molecular Dynamics (REMD) simulations starting 
from a fully extended conformation of peptide 10 (φ = ψ = ω = 180°), according to the protocol 
reported in our previous studies.8a,9c,9h The resulting trajectory, extracted from each replica in order 
to simulate a constant temperature of  308.5 K, was then analyzed in terms of H-bonds, secondary 
structure and cluster analyses (Tables 1-3, Figure 7). 
Table 1. Results of DSSP analysisa of the 100 ns REMD trajectory obtained at T = 308.53 K 
#Residue 310-helix α-helix Turn 
Oxo-Azn1 31.1 3.6 19.7 
Ala2 34.7  3.6 25.8 
Aib3 34.7 3.6 31.5 
Ala4 18.7 3.6 30.0 
a Values are reported as a percentage of the total secondary structures populations. The difference 
to 100% is the percentage of unordered secondary structure. 
 
Table 2. Results of H-Bond analysis of the 50-100 ns REMD trajectory at T = 308.53 K 
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Acceptor Donor Occ% AvgDista (Å) AvgAngb (deg.) 
Ph C=O Aib3 NH 37.0 3.20 163.1 
Ala2 C=O NHMe 27.0 3.13 160.5 
oxo-Azn1 C=O Ala4 NH 19.1 3.32 162.0 
oxo-Azn1 C=O NHMe 5.3 3.13 161.9 
Ph C=O Ala4 NH 3.9 3.42 162.9 
aDonor-acceptor distance; cutoff = 4.0 Å. bDonor-H-acceptor angle; cutoff = 150 deg. 
 
Table 3. Average dihedrals obtained from the analysis of the three most populated cluster 
trajectory 
 #1 #2 #3 #4 #5 
φ1 -29±35 15±43 22±41 -16±43 33±29 
ψ1 -33±35 18±47 23±47 -20±43 35±32 
φ2 -60±26 -87±48 -93±40 -64±41 35±44 
ψ2 -22±19 111±81 132±69 4±46 32±17 
φ3 -45±13 -22±38 40±19 22±38 46±9 
ψ3 -44±29 -24±55 27±63 7±72 43±16 
φ4 -85±27 -87±35 -75±60 -87±44 -78±55 
ψ4 16±65 49.±81 87±86 80±91 70±92 
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Figure 7. Representative structure and relative population (%) of the most populated clusters 
obtained by cluster analysis of the 50-100ns REMD trajectory obtained at T = 308.53 K 
 
Results show that Oxo-Azn has an helical propensity similar to that observed for the parent Azn8a,9c 
suggesting that neither the lactame C=O nor the substituted chain at the nitrogen azepino negatively 
affect the ability to stabilize helical conformations. Indeed, the DSSP analysis of the REMD 308.53 
K (Table1) trajectory shows a relatively high helical content for residues 1-3, with turn content being 
prevalent only for the C-terminal residue Ala4. It can also be observed that the helical content is 
principally due to 310 helix conformation, with only a marginal contribution of α-helix. This is also 
confirmed by H-bond analysis (Table 2), since relevant H-bonds are those of the i → i+3 type (Ph 
C=O∙∙∙HN Aib3, Oxo-Azn C=O∙∙∙HN Ala4 and Ala2 C=O∙∙∙HNMe), typical of 310 helices, while i 
→ i+4 H-bonds show occupancies of about 5%. Finally, geometrical clusterization (Figure 8) 
followed by the analysis of relevant φ and ψ dihedrals (Table 3) showed an helical conformation as 
the well-defined secondary structure most frequently sampled during the simulation (cluster #1, 
pop% = 41.3, Figure 7), even if structures classifiable as different folding intermediates (clusters 
#2-5) represent about 60% of the whole conformational population. By observing the average φ and 
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ψ values of the most populated cluster #1, it can be observed that most dihedrals fall within the 
range typical of 310 helix (even if an α-helix cannot be excluded, if deviations from the average 
values are considered).13 Further details on the folding preferences of peptide 10 were also provided 
by the analysis of the 3D Ramachandran plot derived from the 100 ns REMD trajectory obtained at 
308.53 K (Figure 8). 
 
 
Figure 8. 3D Ramachandran plot obtained from the 100 ns REMD trajectory (308.53 K) of peptide 
10. The z-axis represents the frequency of occurrence. 
It can be observed that the most frequently sampled couple of φ and ψ dihedrals is that typical of 
the right-handed helix secondary structure, followed by a not negligible amount of left handed helix. 
Dihedral values belonging to the β regions are also sampled and, interestingly, the paths connecting 
the different regions of the 3D-Ramachandran plot can also be observed as ruffles on the graph 
surface, which indicate high energy conformations which are only occasionally sampled.  
Use of scaffold 5 for gold nanoparticles preparation. Finally, we investigated the possibility of 
using scaffold 5 for the obtainment of covered gold nanoparticles.  
First, we introduced a thiol tether through an ester linkage with the hydroxy function of scaffold 5. 
3-Tritylsulfanyl-propionic acid was condensed with scaffold 5 using DCC and DMAP (CH2Cl2, 25 
°C, h) affording compound 12 (80%, Scheme 3).  
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Scheme 3. Condensation between 5a and 3-tritylsulfanyl propionic acid. 
Gold nanoparticles (AuNp) were prepared by chemical reduction (with NaBH4) in a methanol/water 
mixture of the corresponding tetrachlorohydrate salts in the presence of the amino acid conjugate 
12.6b The resulting dark-brown nanoparticle conjugated were found well soluble in organic solvents 
as CH2Cl2 and CHCl3. Transmission electron microscopy analysis (TEM) revealed the formation of 
AuNp-12 conjugated with a metallic core average diameter of 1.8 nm (Figure 9A and B, 
respectively). Moreover, termogravimetric analysis (TGA) showed a 55% weight  loss, which is to 
attributed to the organic part of the cluster, thus to confirm the effective incorporation of 12 over 
the nanoparticle surface (Figure 9C). 
Figure 9. A) TEM image showing the formation of AuNp-12 conjugated. Insert, detailed  view of 
the AuNp-12 conjugated. B) AuNp-12 conjugated size distribution graph showing an average 
diameter of 1.8 nm. C) TGA analysis of AuNp-12 conjugated showing a 55% of weight loss to be 
referred to the organic part of the cluster. 
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Furthermore, UV-Vis absorption spectra and dynamics light scattering (DLS), both recorded in 
CH2Cl2 solution, supported the formation of such nanoparticles (Figure 10A and B respectively).  
In particular, UV-Vis absorption spectra showed a continue absorption profile in the 300-700 
absorption region, and this finding is typical for gold nanoparticle with diameter size below 2 nm.14 
Dynamic light scattering (DLS) analysis revealed 5 nm particle size distribution, which are in 
according with the bulky nature of the ligand.  Moreover, IR (KBr) analysis showed typical amide 
bond signals [v: 3297 (NH-amides), 1734 (CO esters), 1651 (CO amide I), 1546 (CO amide II) cm-
1] that confirmed the occurrence of AuNp-12 conjugation by showing the preservation of the 
functional groups of 5a after its link to the gold core. 
 
 
Figure 10. A) UV-Vis absorption spectra in CH2Cl2 solution of AuNp-12 conjugated. B) DLS 
distribution of AuNp-12 conjugated recorded in a CH2Cl2 solution.  
Interestingly, AuNp-12 presents a dichroic spectrum in the 350-680 nm region (Figure 11), which 
can be attributed to the gold core. In particular, the CD spectrum of AuNp-12 showed two positive 
bands located at 300 (intense) and 500 (broad) nm, while at 400 nm displayed a weak negative band. 
Similar findings were reported in literature, and attributed to metal-chiral ligands interactions15 that 
enhanced the intrinsic chirality of the Au core.16 
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Figure 11. CD spectrum of AuNps 12 in dioxane at 20 °C in the 250-680 nm region. 
 
Finally, by combining information from TEM and TGA analyses we may propose a structural 
information of AuNp-12 conjugated, that result in a chemical formula of Au201L60. 
 In conclusion, the new glutamine analogue oxo-Azn functionalized on the nitrogen side chain 
with a hydroxyalkyl tether was efficiently synthesized in enantiopure form and in gram scale by an 
asymmetric one-step procedure. Both theoretical and dynamic NMR studies revealed that R-oxo-
Azn is a good 310-helix inducer when inserted at the N-terminus in short peptide sequence. Finally, 
the presence of the tethering group allowed the preparation of covered chiral gold nanoparticles. 
Considering the above-mentioned helical stabilization of oxo-Azn in solution, it will be noteworthy 
in the future to deeply investigate if this ability is maintained also when linked to gold nanoparticles. 
  
300 400 500 600
-1,0
-0,5
0,0
0,5
1,0
C
D
 (
m
D
e
g
)
 (nm)
 17 
EXPERIMENTAL SECTION 
The materials and solvents were purchased from common commercial sources and used without 
additional purification. 1H NMR spectra were recorded at 200, 400 or 500 MHz and 13C NMR 
spectra at 50, 70 or 125 MHz using TMS as internal standard. The following abbreviations were 
used to describe peak patterns where appropriate: singlet (s), doublet (d), triplet (t), multiplet (m), 
broad resonances (br). Coupling constants (J) are reported in Hertz. Mass spectra were recorded 
under electron spray interface (ESI) conditions.I nfrared spectra were recorded on a FTIR 
spectrometer. [α]D Values were measured using CHCl3 as the solvent, if not differently reported. 
UV-Vis absorption spectra were measured in water on a UV-Vis spectrophotometer with 1 cm path 
length quartz cuvettes. Samples for transmission electron microscopy (TEM) were prepared before 
use, by 100-fold  dilution of a 2mg/ml water solution of the AuNp. A glow discharged carbon coated 
grid was floated on a small drop of solution and excess was removed by #50 hardened filter paper. 
Thermogravimetric analysis (TGA) was run on 5 mg nanoparticle samples from 25 to 1200 °C under 
a continuous N2 flow. 
Theoretical calculations. The charge parameterization of the unnatural oxo-Azn amino acid has 
been performed as previously reported.8a, 9c Briefly, the oxo-Azn structure was designed with 
MOE,17 capped with an acetyl (Ac) and a NHMe group at the N- and C-termini, respectively, and 
submitted to a conformational search with MOE using the following setup: Low Mode MD, 
MMFF94x force field, Born solvation, iteration limit = 40000, MM iteration limit = 2500, rejection 
limit = 500. The two lowest energy conformations having φ and ψ dihedrals matching a right- or a 
left-handed helix (φ = ±60°, ψ = ±45°) were selected for charge parameterization with R.E.D.IV.18 
The geometries were than optimized at the HF/6-31G(d) level and two different spatial orientations 
were used to derive RESP-A1 charges. Charge restraints of −0.4157, 0.2719, 0.5973 and −0.5679 
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were imposed to the backbone nitrogen, hydrogen, carbonyl carbon and oxygen, respectively, 
accordingly to the Amber ff99SB force field.19 
REMD simulations were carried out on model peptide 10 by starting from an extended 
conformation (ψ=φ=ω= 180°) and by following a previously reported protocol, 8a, 9c  which is 
hereafter summarized: 12 replicas were run for 100 ns at temperatures from 260.00 to 658.94 K, 
using the pmemd module of Amber14,20 and selecting the ff99SB force field coupled with the GB-
OBC(II) implicit solvent model.21 The trajectories were extracted at 308.53 K and the simulation 
convergence was assessed on the basis of cluster analyses performed with cpptraj20at 25-50, 50-75 
and 75-100 ns time intervals. The simulations resulted fully converged already at 50 ns, and the 
subsequent H-bond and clustering analyses were then conducted on the 50-100 ns interval. H-bonds 
were analyzed with VMD 1.9.1,22 with a donor−acceptor distance threshold of 4.0 Å and an angle 
cutoff of 30°. Secondary structure analyses were performed on the whole trajectory by using the 
DSSP method,23 as implemented in cpptraj. 
General Procedure for the Schmidt Reaction. Method A) Ketone 19c (11g, 40 mmol) was 
dissolved in dry CH2Cl2 (300 mL) under nitrogen atmosphere. After cooling at -10°C, BF3(OEt)2 
(26.5 mL, 200 mmol) was dropped and the mixture was stand for 30 min after which azide 2a or 2b 
(1.3 equiv.), dissolved in CH2Cl2 (200 mL), was added. The stirring was continued (TLC: 
CH2Cl2/MeOH, 10:1) and the temperature was gradually increased to 25°C in 18h period. A solution 
of NaOH (2N, until pH 14) was added and the mixture was stirred for 30 min.. A white solid, 
corresponding to the isomer 6, was formed and filtered. The organic layer was separated and the 
aqueous one was extracted with CH2Cl2 (3 x 50 mL). The organic layers were washed with a 
saturated solution of NH4Cl (pH 4). After drying over Na2SO4 and solvent evaporation, the crude 
mixture was chromatographed on silica gel affording diastereoisomers 5 and 6. Method B). The 
reaction of azide 2a (275 mg, 1.3 mmol) and ketone 1 (300 mg, 1.1 mmol) was performed according 
to point a) but avoiding the quenching with NaOH. After solvent evaporation, 1H NMR analysis of 
the crude mixture showed the formation of a mixture of 3a/4a in 67:33. The reaction mixture was 
taken up with Et2O affording pure compound 4a (60 mg, 13%), that was collected by filtration. The 
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mother liquors were chromatographed (CH2Cl2/MeOH, from 100:0 to 50:1) affording 5a (210 mg, 
45%) and 6a (50mg, 10%). 
Methyl 5-Benzoylamino-1-[(S)-1-hydroxy-3-phenylpropan-2-yl]-2-oxoazepan-5-carboxylate 
(5a/6a): 67:33. Column chromatoghraphy condition:CH2Cl2/MeOH, from 100:0 to 10:1 
(R)-5a: 8.5 g, 47%. Mp 234 °C (CH2Cl2/MeOH); []D25 -24.7 (c 0.2, DMSO); IR (KBr) νmax 3340, 
1723, 1660 cm-1; 1H NMR (DMSO-d6, 500 MHz)  8.55 (s, 1H, exch.), 7.84 (d, J 7.1, 2H), 7.57-
7.18 (m, 8H), 4.77 (t, J 5.3, 1H, exch.), 4.74 (brs, 1H), 3.56 (s, 3H, OMe), 3.54-3.48 (m, 2H), 3.45-
3.39 (m, 1H), 3.35-3.27 (m, 1H), 2.86 (dd, J 15.2, 6.3, 1H), 2.75 (dd, J 15.2, 9.5,1H), 2.65-2.55 (m, 
1H), 2.30-2.18 (m, 2H), 2.14-2.05 (m, 1H), 1.85-1.68 (m, 2H); 13C NMR (DMSO-d6, 125 MHz)  
28.2, 31.3, 34.1, 34.6, 38.2, 51.7, 55.8, 59.9, 60.9, 125.7, 127.5 (x2), 127.9 (x4), 128.4 (x2), 131.2, 
133.8, 138.6, 166.6, 173.4, 173.9; MS (ESI+) 447.3 [M+23] C24H28N2O5 Calcd for: C, 67.91; H, 
6.65; N, 6.60; Found: C, 67.78; H, 6.80; N, 6.49.  
(S)-6a: 4.1 g, 23%. Mp 230 °C dec. (CH2Cl2/n-hexane); [α]D25 -47.7 (c 0.1, DMSO); max 3435, 
1737, 1627cm-1; 1H NMR (DMSO-d6, 500 Mz)  8.51 (s, 1H, exch.), 7.82 (d, J 7.1, 2H), 7.58-7.15 
(m, 8H), 4.75 (t, J 4.8, 1H, exch.), 4.54 (brs, 1H), 3.58 (s, 3H), 3.55-3.42 (m, 3H), 3.35-3.22 (m, 
1H), 2.24-2.71 (m, 2H), 2.66 (dd, J 13.1, 13.6, 1H), 2.38-2.28 (m, 1H), 2.25-2.07 (m, 2H), 1.83 (dd, 
J 13.5, 12.8, 1H), 1.81-1.70 (brs, 1H); 13C NMR (DMSO-d6, 125 Mz)  28.2, 31.2, 34.1, 34.3, 39.1, 
51.7, 57.8, 60.1, 60.9, 125.7, 127.5 (x2), 127.9 (x2), 127.9 (x2), 128.6 (x2), 131.2, 133.9, 138.8, 
166.9, 173.6, 173.9; MS (ESI+) 447.2 [M+23] C24H28N2O5 Calcd for: C, 67.91; H, 6.65; N, 6.60; 
Found: C, 67.78; H, 6.80; N, 6.49.  
Methyl 5-Benzoylamino-1-[(S)-2-hydroxy-1-phenylethyl]-2-oxoazepan-5-carboxylate 
(5b/6b): 50:50. Column chromatoghraphy condition: CH2Cl2/MeOH, from 100:0 to 50:1 
(R)-5b: 5.7 g, 35% Mp 260 °C (CH2Cl2/MeOH); [α]D25 +13.2 (c 0.2, MeOH); IR (KBr)νmax3359, 
1726, 1624 cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 8.58 (s, 1H, exch), 7.84 (d, J 8.2, 2H), 7.58-
7.25 (m, 8H), 5.63 (t, J 6.8, 1H),4.93 (brs, 1H, exch), 3.88 (t, J 4.7, 2H), 3.54 (s, 3H), 3.56-3.54; 
3.30-3.20 (2 m, 2H), 2.74 (dd, J 2.5, 2.0, 1H), 2.55-2.25 (m, 2H), 2.10-1.85 (m, 2H), 1.50 (br, 1H);  
13C NMR (DMSO-d6, 75 Mz) δ29.6, 32.3, 35.5, 39.3, 52.8, 58.0, 60.6, 61.0, 128.1, 128.6 (x2), 128.7 
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(x2), 129.0 (x2), 129.2 (x2), 132.3, 134.9, 139.5, 167.7, 174.5, 174.9; MS (ESI+) 411.2 [M+1], 
433.3 [M+23] C23H26N2O5, Calcd for: C, 67.30; H, 6.38; N, 6.82; Found: C, 67.01; H, 6.55; N, 6.63. 
(S)-6b: (trace amount of 5b are present); 4.9g, 30%, IR (KBr) νmax 3412, 1738, 1627 cm-1; 1H NMR 
(DMSO-d6, 300 MHz) δ8.49 (s, 1H, exch.), 7.85 (d, J 7.2, 2H.), 7.56-7.20 (m, 8H.), 5.66 (dd, J 13.8, 
5.9, 1H), 4.93 (t, J 4.8, 1H, exch), 4.00-3.75 (m, 2H), 3.60 (s, 3H), 3.53 (dd, J 15.9, 10.1, 1H), 3.13 
(dd, J 15.9, 6.1, 1H), 2.89 (t, J 13.5, 1H), 2.60-2.40 (m, 1H), 2.28 (dd, J 14.5, 8.3, 1H), 2.25-2.10 
(m, 1H), 2.10-1.85 (m, 2H); 13C NMR (DMSO-d6, 75 MHz) δ29.1, 32.1, 35.8, 39.4, 52.9, 57.9, 60.5, 
61.3, 127.9, 128.4 (x2), 128.7 (x2), 129.0 (x2), 129.2 (x2), 132.2, 135.0, 139.7, 167.9, 174.8, 175.5; 
MS (ESI+) 411.4 [M+1], 433.4 [M+23],C23H26N2O5. Calcd for: C, 67.30; H, 6.38; N, 6.82; Found: 
C, 66.97; H, 6.54; N, 6.58. 
 
Methyl 7-benzoylamino-(S)-3-benzyl-3,5,6,7,8,9-hexahydro-oxazolo[3,2-a]azepinium-7-
carboxylate . BF4- (3a/4a): 67:33.  
(R)-3a (mixture with (S)-4a): 1H NMR (CDCl3, 500 MHz) main signals: δ 7.92 (d, J 7.1, 2H), 4.91 
(m, 1H), 4.70 (m, 1H), 4.68 (m, 1H), 4.10-4.00 (m, 1H), 3.69 (s, 3H, OMe), 2.00-1.70 (m, 2H); 13C 
NMR (CDCl3, 125 MHz) δ 23.1, 27.7, 29.7, 32.1, 36.7, 42.5, 53.1, 60.2, 65.6, 76.3, 127.6 (x2), 
127.9, 128.6 (x2), 129.2 (x2), 129.4 (x2), 132.2, 132.8, 133.5, 167.9, 173.1, 179.0. 
(S)-4a: νmax 3400, 1738, 1661 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.88 (d, J 7.2, 2H), 7.50-7.46 (m, 
1H), 7.42-7-37 (m, 5H), 7.36-7.33( m, 1H), 7.22 (d, J 6.9, 2H), 5.03 (dd, J 9.8, 9.3, 1H), 4.97-4.90 
(m, 1H),  4.68 (dd, J 9.3, 5.9, 1H), 3.98 (dd, J 15.1, 8.5, 1H), 3.81 (dd, J 15.1, 9.3, 1H), 3.74 (s, 3H), 
3.25 (dd, J14.4, 5.0, 1H), 3.09 (dd, J 17.7, 10.3, 1H), 3.04 (dd, J 14.4, 7.5, 1H), 2.86 (dd, J 17.7, 
8.8, 1H), 2.82 (dd, J 16.7, 9.2, 1H), 2.67 (ddd, J 16.3, 9.0, 1.6, 1H), 2.30-2.59 (dd, J 15.6, 8.3 1H), 
2.54 (ddd, J 16.3, 13.5, 1.8, 1H); 13C NMR (CDCl3, 125 MHz) δ 21.9, 26.4, 31.4, 36.3, 41.8, 52.3, 
59.2, 64.6, 75.5, 126.8(x2), 127.5, 127.9 (x2), 128.5 (x2), 128.8 (x2), 131.4, 132.1, 132.2, 166.9, 
172.2, 178.6; MS (ESI+) 407.3 [M]+ C24H27N2O4. Calcd for: C, 70.74; H, 6.68; N, 6.87; Found: C, 
70.62; H, 6.90; N, 6.68 
(R)-5-Benzoylamino-1-[(S)-1-hydroxy-3-phenylpropan-2-yl]-2-oxoazepane-5-carboxylic acid 
(7). Ester 5a (300 mg, 0.7 mmol) was dissolved in CH2Cl2/MeOH (9:1, 10.5 mL). A  methanolic 
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solution of NaOH (2N, 1.13 mL) was added and the mixture was stirred at 25 °C for 15 h (TLC: 
CH2Cl2/MeOH, 10:1). After solvent evaporation, the mixture was taken up with H2O and acidified 
12 N with HCl until pH 1. A solid was separated and filtered corresponding to acid 7 (220 mg). The 
aqueous solution was extracted with CH2Cl2 (3 x 3 mL). The organic layers were then dried over 
Na2SO4 and the solvent was removed under vacuum. After crystallization, a further crop of pure 
compound 7 was obtained (50 mg). Acid 7 (270 mg) was obtained in 95% overall yield.  
Mp: 180 °C (Et2O); [αD]25 +18.3 (c 0.1, MeOH); IR (KBr) νmax 3353, 2923, 1720 cm-1; 1H NMR 
(DMSO-d6, 300 MHz) δ 12.28 (brs, 1H), δ 8.40 (s, 1H), 7.84 (d, J 7, 2H), 7.59-7.17 (m, 8H), 4.93-
4.71 (m, 1H), 4.30 (brs, 1H), 3.65-3.27 (m, 4H), 2.97-2.70 (m, 2H), 2.63-2.42 (m, 1H), 2.38-2.01 
(m, 3H), 1.98-1.80 (m, 2H); 13C NMR (DMSO-d6, 75 MHz) δ 29.3, 32.5, 35.2, 35.8, 42.1, 57.2, 
61.9, 65.4, 126.8, 128.5(x2), 128.9(x 2), 129.0(x2), 129.5(x2), 132.1, 135.2, 139.7, 162.3, 175.1, 
175.4; MS (ESI-) 409.6 [M-1]. C23H26N2O5 Calcd for: C, 67.30; H, 6.38; N, 6.82; Found: C, 67.13; 
H, 6.53; N, 7.01.  
Synthesis of dipeptide 8. Benzyl ester of (L)-alanine p-toluenesulfonate (200 mg, 1.11 mmol) was 
suspended in CH2Cl2 (5 mL) and then treated with triethylamine (155 μL, 1.11 mmol). The mixture 
was washed with H2O. The organic layer was dried over Na2SO4 and the solvent was evaporated 
under vacuum. Acid 7 (130 mg, 0.320 mmol) was dissolved in a mixture of CH2Cl2 (3.2 mL)/DMF 
(0.1 mL) mixture. After cooling to 0°C, HOAt (44 mg, 0.320 mmol), EDC (61 mg, 0.320 mmol), 
alanine benzyl ester (170 mg, 0.950 mmol) and DIPEA (2 equiv., 0.112 mL, until pH 8) were added 
to the mixture. The reaction was left under stirring overnight at 25 °C (TLC: CH2Cl2/MeOH, 10:1). 
The crude was washed with aqueous HCl (3N, 2 x 5 mL), H2O (5 mL) and finally with NaHCO3 (2 
x 5 mL). The organic layer was dried over Na2SO4 and the solvent was evaporated under vacuum. 
The crude mixture was crystallized affording pure compound 13 (185 mg, 80%). Mp: 120 °C 
(CH2Cl2/Et2O); [αD]25 -27.5 (c 0.1, MeOH); IR (KBr) νmax  3400, 1740 cm-1; 1H NMR (CDCl3, 300 
MHz) δ 7.77 (d, J 6.9, 2H), 7.48-7.14 (m, 14 H), 7.01 (s, 1H), 5.11 (q, J 11.9 , 2H), 4.70 (brs, 1H), 
4.53 (t, J 14.07, 1H), 3.72-3.57 (m, 2H), 3.46-3.26 (m, 2H), 2.85-2.52 (m, 4H), 2.29-2.02 (m, 4H), 
1.38-1.27 (m, 3H), 1.27 (s, 1H); 13C NMR (CDCl3, 75 MHz) δ 18.3, 29.3, 32.3, 35.2, 36.1, 40.9, 
48.8, 59.5, 61.6, 63.1, 67.4, 127.0, 127.2, 127.4, 127.7, 128.4 128.5 (x2), 128.6, 128.7, 128.9, 129.0, 
129.1, 129.3, 129.8, 132.3, 134.4, 135.7, 138.2, 168.4, 172.9, 173.1, 176.4; MS (ESI-) 570.9 [M-1]. 
C33H37N3O6 Calcd for: C, 69.33; H, 6.52; N, 7.35; Found: C, 69.57; H, 6.23; N, 7.04.   
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Debenzylation of ester 8. Ester 8 (100 mg, 0.175 mmol) was dissolved in MeOH (5 mL). Pd/C 
(185 mg, 0.175 mmol) was added and the mixture was hydrogenated at 25 °C overnight (TLC: 
CH2Cl2/MeOH, 10:1). The catalyst was filtered on a celite pad and acid 9 (75 mg, 90%) was 
obtained after crystallization. Mp: 140°C (CH2Cl2/Et2O); [αD]25 -20.8 (c 0.2, MeOH); IR (KBr) νmax 
3400, 2928, 1730, 1629 cm-1; 1H NMR (CD3OD, 300 MHz) 7.85-7.82 (m, 2H), 7.57-7.43 (m, 3H), 
7.31-7.19 (m, 5H), 4.32 (q, J 7.1, 1H), 3.76-3.63 (m, 2H), 3.55 (brs, 2H), 3.36-3.31 (m, 2H), 2.92-
2.78 (m, 2H), 2.61-2.41 (m, 3H), 2.23-2.01 (m, 3H), 1.35 (d, J 7.1, 3H); 13C NMR (CD3OD, 75 
MHz) δ 17.2, 28.3, 31.8, 34.8, 35.6, 39.8, 48.6, 49.2, 58.6, 61.6, 126.5, 127.5, 127.6, 127.7, 
128.5(x2), 128.8(x2), 129.1, 131.8, 134.8, 138.5, 169.5, 174.1, 175.8, 176.8; MS (ESI+) 504.3 
[M+23]. C26H31N3O6 Calcd. for: C, 64.85; H, 6.49; N, 8.73; Found: C, 64.56; H, 6.78; N, 8.46;  
Synthesis of tetrapeptide 10. Acid 9 (60 mg, 0.125 mmol) was suspended in a mixture of CH2Cl2 
(1.25 mL)/DMF (0.1 mL). After cooling to 0°C, HOAt (17 mg, 0.125 mmol), EDC (24 mg, 0.125 
mmol), dipeptide H2N-Aib-(L)-AlaNHMe (60 mg, 0.312 mmol) and DIPEA (2 equiv., 0.044 mL, 
until pH 8) were added to the mixture. The reaction was stirred at 25°C overnight (TLC: 
CH2Cl2/MeOH, 10:1). The mixture was washed with aqueous  HCl (3N, 2 x 5 mL), H2O (5 mL) and 
finally with NaHCO3 (2 x 5 mL). The organic layer was dried over Na2SO4 and the solvent was 
evaporated under vacuum. The crude mixture was crystallized from CH2Cl2/Et2O affording crude 
peptide 10 (40 mg, 50%). A further purification was performed by HPLC (phase A: 95% H2O, 5% 
CH3CN, 1 mL TFA; phase B: 95% CH3CN, 5% H2O, 1 mL TFA; elution gradient: 95% A for 5 
min, then 95-30% A in 20 min) to give peptide 10 (20 mg, 25%). During the purification we 
observed the formation of a by-product, corresponding to the bicyclic derivative 11. Alternatively, 
pure peptide 10 (30 mg, 38%) can be directly obtained from the crude by performing a second 
crystallization. Mp: 120°C (CH2Cl2/Et2O); [αD]25 +6.2 (c 0.2, MeOH); IR (KBr) νmax  3400, 1740 
cm-1; 1H NMR (CD3CN, 300 MHz) δ 8.92 (s, 1H), 7.94 (d, J 7.2, 2H), 7.69 (brs, 1H), 7.60 (d, J 
10.9, 1H), 7.54-7.51 (m, 3H), 7.45 (d, J 3.9, 1H), 7.39-7.17 (m, 7H), 4.71 (brs, 1H), 4.26-4.08 (m, 
1H), 3.93-3.87 (m, 1H), 3.70-3.31 (m, 4H), 3.13-3.03 (m, 1H), 2.83-2.71 (m, 2H), 2.66 (d, J 4.6, 
3H), 2.59-1.90 (m, 5H), 1.55-1.32 (m, 12H); 13C NMR (CD3CN, 75 MHz) δ 15.8, 16.9, 23.0, 25.3, 
26.4, 28.5, 30.1, 31.5, 34.3, 36.5, 42.7, 49.7, 52.4, 56.6 , 62.0, 65.5, 126.1, 127.8, 128.4, 128.6, 
129.1, 129.5, 130.3, 132.0, 132.3, 133.7, 134.2, 139.0, 167.8, 168.5, 173.2, 174.1, 174.5, 175.5; MS 
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(ESI+) 651.3 [M+1]. C34H46N6O7 Calcd. for: C, 62.75; H, 7.12; N, 12.91; Found: C, 62.56; H, 7.34; 
N, 13.17. 
Synthesis of 12. Alcohol 5a (0.26 mmol) was dissolved in CH2Cl2 (3 mL) and 3-tritylsulfanyl-
propionic acid (100 mg, 0.286 mmol) was added. After cooling to 0°C, DMAP (3 mg, 0.026 mmol) 
was added and DCC (36 mg, 0.286 mmol) dissolved in CH2Cl2 (1 mL) was dropped to the solution. 
The reaction was stirred for 3h at 25 °C (TLC: CH2Cl2/AcOEt, 1:1). The mixture was washed with 
NaHCO3 (5 mL) and H2O (5 mL). The organic layer was dried over Na2SO4 and the solvent was 
evaporated under vacuum. Pure compound 12 (155 mg, 80%) was obtained after crystallization. 
Mp: 80°C (AcOEt/Et2O); [αD]25 -8.7 (c 0.2, MeOH); IR (KBr) νmax 3326, 1738 cm-1; 1H NMR 
(CDCl3, 200 MHz) δ 7.77-7.70 (m, 2H), 7.51-7.17 (m, 23H), 6.09 (bs, 1H), 5.01-4.76 (m, 1H), 4.74 
(bs, 1 H), 4.39-4.01 (m, 2H), 3.69 (s, 3H), 3.39-3.21 (m, 3H), 2.94-2.84 (m, 2H), 2.59-2.45 (m, 2H), 
2.02-1.45 (m, 6H); 13C NMR (CDCl3, 75 MHz) δ 24.5, 24.7, 25.5, 29.8, 33.3, 33.8, 35.3, 50.5, 52.8, 
60.6, 64.3, 67.2, 126.9 (x4), 127.2(x2), 127.4(x2), 127.9, 128.1(x4), 128.4, 128.7, 128.8, 129.1, 
129.2, 129.5, 129.7, 129.8(x4), 132.1, 134.0, 137.6, 144.7, 147.1, 157.8, 167.4, 171.7, 173.2, 174.9; 
MS (ESI+) 777.5 [M+23]. C46H46N2O6S Calcd  for: C, 73.18; H, 6.14; N, 3.71; Found: C, 72.91; H, 
6.35; N, 3.65. 
Preparation of covered gold nanoparticles. In a typical experiment 12 (0.5 mmol) and 
HAuCl4
.3H2O (0.25 mmol) were combined in a 4:1 methanol/milli-Q  water solvent mixture (10 
ml). The resulting solution was allowed to stand at 0°C for 1 h under stirring. To this solution, a 
cold NaBH4 (2.5 mmol) solution in MeOH (2ml) was rapidly added and the resulting mixture was 
stirred at room temperature for additional 4 hrs. The reaction was quenched by addition of  0.1 M 
HCl (1 ml). The solvent mixture was removed under reduced pressure to dryness and the dark 
residue was dissolved in CH2Cl2 (20 ml), washed with H2O, dried over anhydrous Na2SO4, and 
evaporated to dryness. Subsequently, the crude was dissolved in MEOH, passed through a 20 m 
microfilter and afterward precipitated by adding a large amount of Et2O. Finally, the corresponding 
AuNp was obtained after centrifugation. 
Determination of AuNp-12 conjugated structural information. 
The number of Au atoms in the relative AuNps were calculated from: a) dimension of the metallic 
core (diameter) observed in the TEM images,b) the density of bulk metal (55 atoms/nm3), c) 
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applying the sphere model.  The numbers of moieties conjugated to the inorganic cluster were 
calculated from the TGA weight losses (corresponding to the weight fractions of the organic coating 
monolayer on the inorganic cluster) and the molecular weight of the related oligomers conjugated 
to the inorganic core. Consequently, the oligomer footprints of the different AuNps were calculated 
by relating the number of oligomers linked on the gold surface with the dimensional information 
obtained by the TEM analysis.  
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